Inogen Announces Fourth Quarter and Full Year 2019 Financial Results and Updates 2020 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Inogen (INGN) Misses Q4 EPS by 16c, Revenues Miss; Offers FY20 Revenue Guidance Below Consensus
February 25, 2020 4:43 PM ESTInogen (NASDAQ: INGN) reported Q4 EPS of ($0.06), $0.16 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $86.42 million.
Fourth Quarter 2019 Highlights
Total revenue of $78.9 millionInogen One G5® units accounted for over 40% of total unit volume in the periodLimited launch of the Inogen Tidal Assist® Ventilator (TAV®) product in December 2019As of December 31, 2019, the Company had 329 inside direct-to-consumer sales representatives and 17 outside physician sales representativesWhile 2019 was a challenging year, revenue increased 8.2% over the prior year, excluding the... More
